Key result
Perindopril/indapamide significantly increased flow-mediated dilation from 5.0% to 6.0% (P<0.01) after 24 weeks, whereas atenolol did not.
Why the study?
Does a fixed-dose combination of perindopril/indapamide improve peripheral vascular function compared to atenolol in untreated essential hypertensive patients?
Population
62 untreated essential hypertensive patients
Comparison
Fixed-dose combination of perindopril/indapamide… vs Atenolol (50 mg, daily) for 24 weeks
Design
RCT, randomized, parallel group, double-blind
Follow-up
24 weeks
Authors
Loading...
Supports perindopril/indapamide over atenolol for endothelial function in hypertension; confirms differential vascular effects independent of BP reduction.
RCT (n=62)
Double-blind
parallel group
Does a fixed-dose combination of perindopril/indapamide improve peripheral vascular function compared to atenolol in untreated essential hypertensive patients?
Absolute Event Rate: 6% vs 5.5%
p-value: p=<0.01
A fixed-dose combination of perindopril/indapamide improves endothelium-dependent vasodilation more than atenolol in essential hypertensive patients, independent of blood pressure reduction.
Ghiadoni et al. (2009) conducted an RCT in essential hypertension (n=62). perindopril/indapamide vs. atenolol (50 mg, daily) was evaluated on Brachial artery flow-mediated dilation (FMD) at 24 weeks (p=<0.01). Perindopril/indapamide significantly increased flow-mediated dilation from 5.0% to 6.0% (P<0.01) after 24 weeks, whereas atenolol did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: